Related Experiment Video
Updated: Jul 6, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Hepatocellular carcinoma: radiation therapy.
1Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada. laura.dawson@rmp.uhn.on.ca
Cancer Journal (Sudbury, Mass.)
|April 9, 2008
Summary
High-dose radiation therapy (RT) offers effective treatment for hepatocellular carcinoma (HCC), utilizing advanced techniques like conformal planning and image guidance. Specialized approaches, including charged particle therapy and hepatic arterial radioisotopes, show promise for sustained tumor control with manageable toxicity.
Area of Science:
- Hepatobiliary oncology
- Radiation oncology
- Medical physics
Background:
- Hepatocellular carcinoma (HCC) treatment is limited by whole liver tolerance to radiation therapy (RT).
- Advanced RT techniques enable focal high-dose RT for HCC.
- HCC exhibits vascular properties suggesting potential for targeted therapies.
Purpose of the Study:
- To review advanced radiation therapy strategies for hepatocellular carcinoma.
- To evaluate the safety and efficacy of various RT modalities in HCC treatment.
- To identify future directions for RT in HCC management.
Main Methods:
- Conformal RT planning, breathing motion management, and image-guided RT.
- Use of charged particle therapy for precise dose delivery.
- Hepatic arterial delivery of radioisotopes (e.g., yttrium-90 microspheres).
Main Results:
- Advanced RT techniques allow safe delivery of high-dose RT for HCC.
- Charged particle therapy demonstrates desirable dose distributions with low toxicity.
- Hepatic arterial radioisotopes show activity in HCC, warranting further trials.
- Liver toxicity is a concern in patients with compromised liver reserve.
Conclusions:
- Focal high-dose RT, using advanced techniques, is a viable strategy for HCC.
- Charged particle RT and hepatic arterial radioisotopes offer promising treatment options.
- Combining RT with other therapies or novel agents may improve outcomes for extensive HCC.
